Five‐year on‐treatment variables‐based PPACS model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir‐treated patients
International Journal of Cancer · 2023
DOI: 10.1002/ijc.34704 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Yeonjung Ha und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam-si, South Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Considering the lower risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients receiving long‐term potent antiviral therapy, models predicting HCC after 5 years of therapy are needed. We conducted a multicenter retrospective cohort study to construct and validate a model predicting HCC after 5 years of entecavir (ETV) or tenofovir (TFV) therapy for CHB. The endpoint was HCC after 5 years of ETV/TFV therapy. Information on age, sex, liver cirrhosis (assessed by diagnosis code and confirmed by clinical findings) and type of antiviral agent was obtained at baseline (initiation of ETV/TFV). Laboratory values were collected at baseline and 5 years. Risk factors for HCC were identified in the training set and the final prediction model was validated using the test set. Among 7542 patients, 345 (4.6%) developed HCC after 5 years of ETV/TFV therapy. HCC risk after 5 years of ETV/TFV therapy was increased by 4‐fold in patients with liver cirrhosis than in those without cirrhosis at baseline. Furthermore, P latelet counts and P rothrombin time at 5 years, A ge at baseline and S ex were associated with risk of HCC and were incorporated into a prediction model, PPACS. PPACS showed a good performance with a time‐dependent area under the curve of 0.80 (95% confidence interval, 0.75‐0.85) at 8‐year of ETV/TFV therapy, a Brier score of 0.031 and an integrated Brier score of 0.006 in the test set. In conclusion, the PPACS model provides a reliable assessment of HCC risk after 5 years of ETV/TFV therapy ( https://ppacs.shinyapps.io/shiny_app_up/ ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam-si, South Korea.
- Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
- Department of Biostatistics, Korea University College of Medicine, Seoul, South Korea.
ORCID-Profile: Yeonjung Ha, Ju Hyun Shim
Zitieren
APA
Ha, Y., Lim, J., Chon, Y. E., Kim, M. N., Lee, J. H., Kim, K. M., Shim, J. H., Lee, D., Hwang, S. G., Han, S., & Lee, H. C. (2023). Five‐year on‐treatment variables‐based PPACS model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir‐treated patients. International Journal of Cancer. https://doi.org/10.1002/ijc.34704
Vancouver
Ha Y, Lim J, Chon YE, Kim MN, Lee JH, Kim KM, et al. Five‐year on‐treatment variables‐based PPACS model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir‐treated patients. International Journal of Cancer. 2023. doi:10.1002/ijc.34704
BibTeX
@article{Ha2023,
author = {Ha, Yeonjung and Lim, Jihye and Chon, Young Eun and Kim, Mi Na and Lee, Joo Ho and Kim, Kang Mo and Shim, Ju Hyun and Lee, Danbi and Hwang, Seong Gyu and Han, Seungbong and Lee, Han Chu},
title = {Five‐year on‐treatment variables‐based PPACS model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir‐treated patients},
journal = {International Journal of Cancer},
year = {2023},
doi = {10.1002/ijc.34704}
}
EUVIMED